In prostate cancer cells, adiponectin can prevent neovascularization by suppressing VEGF-A secretion (Gao et al., 2015), and adiponectin treatment has been shown to downregulate VEGF-B and VEGF-D mRNA expression while increasing the serum concentration of the anti-angiogenic factor IL-12 in mouse colon cancer cells (Moon et al., 2013). The gene discussed is ADIPOQ; the disease is prostate cancer.